Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network of 4 hospitals and over 20 medical centres in the UAE.
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
Transformation to pure-play Innovative Medicines company nears completion
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
Nutrigenomics is the study of how genes and diet (nutrients) interact. Gene variants (genetic differences) predict how an individual’s body will respond to certain nutrients.
Expanding precision medicine, ARTIS icono is designed to enable a wide procedure mix in a single interventional suite
The policy aspires to reduce cost of logistics in India to be comparable to global benchmarks by 2030
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
Subscribe To Our Newsletter & Stay Updated